Optison

Optison®

Cardiology A '2nd-generation' ultrasound contrast medium consisting of a solution of gas-filled microbubbles with a mean bubble size 4 µm, range 1–10 µm produced by sonicating a 5% albumin solution. See Sonicated albumin. Cf Albunex®.
References in periodicals archive ?
Recently, commercially available ultrasound contrast agents (UCAs) such as SonoVue and Optison are widely used for ultrasound imaging, because they enhance the blood pool signal due to their large particle size (2-8 [micro]m).
Food and Drug Administration (FDA) to allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) in-house.
Examination of inertial cavitation of Optison in producing sonoporation of chinese hamster ovary cells.
Although Optison is currently the only FDA approved polymer shelled CA and some such as Sonovist (Schering, Berlin) with a cyanoacrylate shell, have been withdrawn due to adverse side effects, the role of CA within the U.
Two ultrasound contrast agents, Definity (Bristol-Meyers Squibb) and Optison (GE Healthcare), are approved in the United States for use to improve suboptimal echocardiograms.
The manufacturers of Definity (perflutren lipid microsphere) injectable suspension and Optison (perflutren protein-type A microspheres for Injection), the only microbubble ultrasound contrast agents approved in the United States, have agreed to add a black box warning and other warnings to the product labels describing these risks.
Optison is a contrast agent that may improve the visualization of the left ventricular border - an area of the heart that is critical to see in order to assess and diagnose certain heart diseases.
Studies should focus on the two contrast agents most commonly used in adults, Optison (perflutren protein-type A microspheres) and Definity (perflutren lipid microspheres), Dr.
For example, after passage through the heart, Albunex lasts for only 15-30 seconds, and Optison for about 2 minutes.
However, recent shortages in DEFINITY have left an opening for GE Healthcare's slightly lower-cost Optison to gain share.
However, two other ultrasound contrast agents -- Optison (GE Healthcare) and Definity (Lantheus Medical Imaging) -- are FDA-approved for cardiac imaging in the United States.
Revised label for contrast agent Optison modifies patient monitoring and observation requirements